On October 21 at the SEOM 2020 Virtual Conference, Dr. Meritxell Bellet Ezquerra of Vall d’Hebrón University Hospital, Barcelona, Spain, presented the results of PARSIFAL, a clinical trial sponsored by MEDSIR.
The PARSIFAL trial was a multicenter, randomized, open-label phase II study that explored the optimal endocrine agent (fulvestrant vs letrozole) to combine with palbociclib as initial therapy for patients with endocrine-sensitive, Estrogen Receptor-[+]/Human Epidermal Growth Factor Receptor 2[–] advanced breast cancer.
The Spanish cohort of patients represented half of the 486 patients included in the global study. It was characterized by having more menopausal patients, with non-measurable disease and visceral disease, compared to the global population. The Spanish cohort was also characterized by having more patients who have had tamoxifen as only drug treatment for advanced disease.
The results showed a nonsignificant difference between fulvestrant and letrozole arms in progression-free survival (PFS). She also noted there was a trend which did not reach a statistical significance when analyzing PFS by visceral disease, with patients with non-visceral disease doing better with fulvestrant, and patients with visceral disease benefiting slightly more from letrozole. The overall response and clinical benefit rates were also similar in both treatment arms and the safety profile was consistent with that reported in previous studies with no unexpected adverse events.
“The main results from the PARSIFAL study were already presented at ASCO Annual Congress in May 2020, but here we showed the final results from the Spanish cohort of patients were consistent and in line with the results obtained globally.” –concluded Dr Bellet Ezquerra.
Get in touch with us if you would like to hear more about our work and ongoing clinical trials.
Comments